Preparing the way for novel blood-based biomarkers and disease-modifying treatments for Alzheimer's disease in the NHS in the UK.
作者信息
Korologou-Linden Roxanna, Middleton Lefkos, Majeed Azeem, Nicholls Dasha, Robinson Oliver, Hayhoe Benedict
机构信息
Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, London W6 8RP, UK.
NIHR Applied Research Collaboration Northwest London, London W12 0BZ, UK.
出版信息
J R Soc Med. 2025 Mar;118(3):78-81. doi: 10.1177/01410768241311139. Epub 2025 Jan 28.
Abstract
摘要
相似文献
1
Preparing the way for novel blood-based biomarkers and disease-modifying treatments for Alzheimer's disease in the NHS in the UK.为英国国民医疗服务体系（NHS）中阿尔茨海默病基于血液的新型生物标志物及疾病修饰治疗方法铺平道路。
J R Soc Med. 2025 Mar;118(3):78-81. doi: 10.1177/01410768241311139. Epub 2025 Jan 28.
2
The patient pathway for mild cognitive impairment due to Alzheimer's disease in Asia: Current practices, barriers, and expert recommendations for optimization.亚洲阿尔茨海默病所致轻度认知障碍的患者诊疗路径：当前实践、障碍及优化的专家建议
J Prev Alzheimers Dis. 2025 Aug;12(7):100215. doi: 10.1016/j.tjpad.2025.100215. Epub 2025 Jun 6.
3
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.脑脊液和血液生物标志物在阿尔茨海默病诊断中的应用：系统评价和荟萃分析。
Lancet Neurol. 2016 Jun;15(7):673-684. doi: 10.1016/S1474-4422(16)00070-3. Epub 2016 Apr 8.
4
Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration.脑源性 tau：阿尔茨海默病型神经退行性变的新型基于血液的生物标志物。
Brain. 2023 Mar 1;146(3):1152-1165. doi: 10.1093/brain/awac407.
5
Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?为早期和临床前阿尔茨海默病干预设计疾病修正药物试验：哪些证据对患者、医护人员和支付方有意义？
J Prev Alzheimers Dis. 2019;6(1):20-26. doi: 10.14283/jpad.2018.42.
6
18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).使用氟代甲磺酸去甲肾上腺素的18F正电子发射断层显像用于轻度认知障碍（MCI）患者中阿尔茨海默病性痴呆及其他痴呆的早期诊断。
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012884. doi: 10.1002/14651858.CD012884.
7
Down syndrome and Alzheimer's disease: insights into biomarkers, clinical symptoms, and pathology.唐氏综合征与阿尔茨海默病：对生物标志物、临床症状及病理学的见解
Lancet Neurol. 2025 Sep;24(9):753-762. doi: 10.1016/S1474-4422(25)00237-6.
8
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).脑脊液tau蛋白及脑脊液tau蛋白与β淀粉样蛋白比值在轻度认知障碍（MCI）患者中用于诊断阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2.
9
The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.多奈哌齐、卡巴拉汀、加兰他敏和美金刚用于治疗阿尔茨海默病的临床疗效及成本效益
Health Technol Assess. 2006 Jan;10(1):iii-iv, ix-xi, 1-160. doi: 10.3310/hta10010.
10
Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).血浆和脑脊液β淀粉样蛋白用于诊断轻度认知障碍（MCI）患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD008782. doi: 10.1002/14651858.CD008782.pub4.
引用本文的文献
1
To quit quietly or not to quit quietly, that is the existential question.是悄悄退出还是不悄悄退出，这是个关乎生存的问题。
J R Soc Med. 2025 Mar;118(3):71. doi: 10.1177/01410768251337079. Epub 2025 Apr 28.
本文引用的文献
1
Estimated Investment Need to Increase England's Capacity to Diagnose Eligibility for an Alzheimer's Treatment to G7 Average Capacity Levels.评估投资需求以提高英国的阿尔茨海默病治疗资格诊断能力，达到 G7 平均水平。
J Prev Alzheimers Dis. 2024;11(4):1022-1029. doi: 10.14283/jpad.2024.24.
2
Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer's Disease. Are We Ready for the New Era?新型阿尔茨海默病血液生物标志物和疾病修饰疗法。我们是否已准备好迎接新时代？
J Prev Alzheimers Dis. 2024;11(4):897-902. doi: 10.14283/jpad.2024.83.
3
Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests.阿尔茨海默病的高精度血液检测在准确性上可与临床脑脊液检测相媲美或优于后者。
Nat Med. 2024 Apr;30(4):1085-1095. doi: 10.1038/s41591-024-02869-z. Epub 2024 Feb 21.
4
Validation, Deployment, and Real-World Implementation of a Modular Toolbox for Alzheimer's Disease Detection and Dementia Risk Reduction: The AD-RIDDLE Project.验证、部署和实际应用用于阿尔茨海默病检测和降低痴呆风险的模块化工具包：AD-RIDDLE 项目。
J Prev Alzheimers Dis. 2024;11(2):329-338. doi: 10.14283/jpad.2024.32.
5
The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.AHEAD 3-45 研究：阿尔茨海默病预防试验设计。
Alzheimers Dement. 2023 Apr;19(4):1227-1233. doi: 10.1002/alz.12748. Epub 2022 Aug 15.
6
Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: Projecting the impact on the cost and wait times.用于阿尔茨海默病病理学的血液生物标志物及疾病修饰治疗的诊断流程：预测对成本和等待时间的影响
Alzheimers Dement (Amst). 2020 Aug 18;12(1):e12081. doi: 10.1002/dad2.12081. eCollection 2020.
7
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.阿尔茨海默病病理生理过程的追踪：动态生物标志物的更新假设模型。
Lancet Neurol. 2013 Feb;12(2):207-16. doi: 10.1016/S1474-4422(12)70291-0.
Zotero 插件